due to drug-induced toxicity in a trial patient (4), while Lexicon Pharmaceuticals stands to gain up to $1 billion ($75 million upfront payment) from an exclusive license agreement with Novo Nordisk A ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has reached the end of its two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for breaches of its code of practice, after showing "significant and ...